Literature DB >> 17166801

Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1.

Sebastien Jacquemont1, Randi J Hagerman, Paul J Hagerman, Maureen A Leehey.   

Abstract

Recent advances in our understanding of the clinical and molecular features of the fragile-X mental-retardation 1 gene, FMR1, highlight the importance of single-gene disorders. 15 years after its discovery, FMR1 continues to reveal new and unexpected clinical presentations and molecular mechanisms. Loss of function of FMR1 is a model for neurodevelopmental and behavioural disorders, including mental retardation, autism, anxiety, and mood instability. In addition, overexpression and CNS toxicity of FMR1 mRNA causes a late-onset neurodegenerative disorder, the fragile-X-associated tremor/ataxia syndrome (FXTAS). A similar mechanism is probably involved in premature ovarian failure, which affects up to 20% of female carriers of an altered FMR1 gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17166801     DOI: 10.1016/S1474-4422(06)70676-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  95 in total

1.  Sleep apnea in fragile X premutation carriers with and without FXTAS.

Authors:  Alyssa Hamlin; Ying Liu; Danh V Nguyen; Flora Tassone; Lin Zhang; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-09-19       Impact factor: 3.568

2.  Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment.

Authors:  Catherine H Choi; Brian P Schoenfeld; Aaron J Bell; Paul Hinchey; Maria Kollaros; Michael J Gertner; Newton H Woo; Michael R Tranfaglia; Mark F Bear; R Suzanne Zukin; Thomas V McDonald; Thomas A Jongens; Sean M J McBride
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

Review 3.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 4.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

5.  Fragile X screening: attitudes of genetic health professionals.

Authors:  Kruti Acharya; Lainie Friedman Ross
Journal:  Am J Med Genet A       Date:  2009-02-15       Impact factor: 2.802

6.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

7.  Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers.

Authors:  P E Adams; J S Adams; D V Nguyen; D Hessl; J A Brunberg; F Tassone; W Zhang; K Koldewyn; S M Rivera; J Grigsby; L Zhang; C Decarli; P J Hagerman; R J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-04-05       Impact factor: 3.568

8.  Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease.

Authors:  Andreea L Seritan; Danh V Nguyen; Sarah Tomaszewski Farias; Ladson Hinton; Jim Grigsby; James A Bourgeois; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

Review 9.  mTOR signaling: at the crossroads of plasticity, memory and disease.

Authors:  Charles A Hoeffer; Eric Klann
Journal:  Trends Neurosci       Date:  2009-12-04       Impact factor: 13.837

10.  Polymerase chain reaction, nuclease digestion, and mass spectrometry based assay for the trinucleotide repeat status of the fragile X mental retardation 1 gene.

Authors:  Eric D Dodds; Flora Tassone; Paul J Hagerman; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2009-07-01       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.